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A B S T R A C T
Recent clinical trials show the eﬃcacy of Adipose-derived Stromal Cells (ASCs) in contrasting the osteoarthritis
scenario. Since it is quite accepted that ASCs act predominantly through a paracrine mechanism, their secretome
may represent a valid therapeutic substitute. The aim of this study was to investigate the eﬀects of ASC con-
ditioned medium (ASC-CM) on TNFα-stimulated human primary articular chondrocytes (CHs).
CHs were treated with 10 ng/ml TNFα and/or ASC-CM (1:5 recipient:donor cell ratio). ASC-CM treatment
blunted TNFα-induced hypertrophy, reducing the levels of Osteocalcin (−37%), Collagen X (−18%) and MMP-
13 activity (−61%). In addition, it decreased MMP-3 activity by 59%. We showed that the reduction of MMP
activity correlates to the abundance of TIMPs (Tissue Inhibitors of MMPs) in ASC secretome (with TIMP-1
exceeding 200 ng/ml and TIMP-2/3 in the ng/ml range) rather than to a direct down-modulation of the ex-
pression and/or release of these proteases. In addition, ASC secretome contains high levels of other cartilage
protecting factors, i.e. OPG and DKK-1.
ASC-CM comprises cartilage-protecting factors and exerts anti-hypertrophic and anti-catabolic eﬀects on
TNFα-stimulated CHs in vitro. Our results support a future use of this cell-derived but cell-free product as a
therapeutic approach in the management of osteoarthritis.
1. Introduction
Osteoarthritis (OA) is a common age-related condition aﬀecting
millions of people worldwide. It is a multifactorial disease whose pa-
thogenesis involves multiple causes, processes and tissues (Martel-
Pelletier et al., 2016). This pathology is characterized by the destruc-
tion of articular cartilage associated with subchondral bone erosion and
inﬂammation. Cartilage damage seems to be one of the earliest disease-
causing events (Berenbaum, 2013). In OA, articular chondrocytes (CHs)
undergo a phenotypic change: from quiescent and stable they engage a
hypertrophic diﬀerentiation, characterized by increased cell prolifera-
tion and altered expression and activity of matrix-degrading enzymes
(matrix metalloproteinases, MMPs) (Singh et al., 2018). The hyper-
trophic shift of CHs starts with the abnormal modulation of several
signaling molecules and transcription factors that leads to the over-
expression of Collagen X and distinct MMPs, such as MMP-1, MMP-9
and MMP-13. Among these enzymes, the latter is considered the main
marker of hypertrophy (Singh et al., 2018). In animal models, the
down-modulation of hypertrophy-inducing factors enhances the re-
sistance to OA development, suggesting the arrest of chondrocyte hy-
pertrophy as a valid therapeutic approach (Bottini et al., 2016). In
addition, several in vitro models of hypertrophic chondrocytes have
been developed treating cells with IL-1β or TNFα, the two major players
in OA physiopathology (Cecil et al., 2009; Platas et al., 2013). Up to
now, most treatments against OA are not curative. Cartilage regenera-
tion does not occur spontaneously and the most common surgical ap-
proaches to circumvent the loss of cartilage, e.g. microfracture, sub-
chondral drilling or autologous cartilage implantation, often lead to the
formation of low-quality ﬁbrocartilage. In the last years, the use of
Mesenchymal Stromal Cells (MSCs) has emerged as a promising tool
(Lopa et al., 2018). Its eﬃcacy in contrasting cartilage damage has been
shown in vitro (Manferdini et al., 2013; Maumus et al., 2013) and in
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vivo (Lee et al., 2007; Xie et al., 2012). Moreover, > 50 clinical trials
have been investigating the safety, feasibility and eﬃcacy of MSC intra-
articular injection (clinicaltrials.gov). Since nowadays it is widely re-
cognized that MSC therapeutic action largely depends on paracrine
mechanisms, the scientiﬁc interest has shifted to their secretome,
namely the conditioned medium (CM). MSC-CM has been successfully
tested in several preclinical models (e.g. Brini et al., 2017; Kay et al.,
2017; Kuljanin et al., 2019), suggesting its promising potential in future
clinical applications. Here, we have investigated the anti-hypertrophic
and anti-catabolic action of Adipose-derived Stromal Cell conditioned
medium (ASC-CM) on an in vitro model of TNFα-stimulated primary
human articular chondrocytes.
2. Methods
2.1. Human primary cells
Human ASCs were isolated from the adipose tissue of 8 healthy
donors (2 males and 6 females; 46 ± 16 y/o) undergoing aesthetic or
prosthetic surgery at IRCCS Galeazzi Orthopaedic Institute, following
previously described protocols (Niada et al., 2016). Human CHs were
isolated from the articular cartilage of the femoral heads collected from
18 patients (11 males and 7 females; 62 ± 11 y/o) undergoing total
hip replacement surgery at the same Clinical Institute (additional in-
formation in supplementary methods). All waste tissues were collected
following the procedure PQ 7.5.125, version 4, dated 22.01.2015, ap-
proved by IRCCS Istituto Ortopedico Galeazzi. Written informed con-
sent was obtained from all the patients.
2.2. Concentrated conditioned media
Conditioned media were collected from about 90–95% conﬂuent
ASCs cultured for 72 h in starving conditions (i.e. without FBS) and
concentrated through Amicon Ultra-15 Centrifugal Filter Devices with
3 kDa cut-oﬀ (Merck Millipore)(Brini et al., 2017; Niada et al., 2018).
The product was concentrated about 40–50 folds becoming handy for in
vitro treatments (ﬁnal volume of 50-60 μl~106 ASCs).
2.3. Cell viability
CHs were stimulated with 10 ng/ml TNFα and/or ASC-CM (added at
a 1:5 recipient to donor cell ratio). Cell viability was assessed by Alamar
Blue assay (Thermo Fisher Scientiﬁc) (Giannasi et al., 2018) before the
ﬁrst treatment and after 3, 5 and 7 days. After 4 h incubation with
Alamar Blue (1:10 dilution), emitted ﬂuorescence was measured using
Wallac Victor II plate reader (Perkin Elmer).
2.4. Analyses of gene and protein expression
CHs were seeded at the density of 8× 103 cells/cm2 in complete
medium with 1% FBS and treated with 10 ng/ml TNFα and/or ASC-CM
(1:5 recipient to donor cell ratio). 24, 48 and 72 h later, cells were
lysed, and total RNA was extracted with RNaeasy kit (Qiagen). cDNA
was synthesized using the High Capacity Reverse-Transcription Kit
(Thermo Fisher Scientiﬁc). The expression levels of the target genes and
of the housekeeping gene TBP were quantiﬁed by RT-qPCR using
TaqMan technology (MMP3: hs00968305_m1; MMP13:
hs00233992_m1; TBP: hs00427600_m1). The real-time PCR was con-
ducted on a StepOne Plus Applied Biosystem apparatus (Life
Technologies). Data were analysed with the 2-ΔΔCt method.
MMP-3, MMP-13 and Collagen X protein expression was assessed
after 1 or 3 days of treatment using western blotting, as described in
supplementary methods.
2.5. Luminex multiplex assay
CH culture supernatants were prepared as described in supple-
mentary methods. The analyses were conducted using MILLIPLEX MAP
Human Bone Panel (HBNMAG-51 K, Millipore), Human MMP Panel 1
and 2 (HMMP1MAG-55 K and HMMP2MAG-55 K), and Human TIMP
Magnetic Luminex Performance Assay (LKTM003, R&D Systems).
Technical duplicates were analysed for each condition (25-50 μl/
sample) and read through Bio-Plex Multiplex System (Bio-Rad) fol-
lowing standard procedures. Data analysis was performed with
MAGPIX xPONENT 4.2 software (Luminex Corporation).
2.6. MMP-3 and MMP-13 activity assay
72-h culture supernatants were analysed to assess the activity of
MMP-3 and MMP-13 with SensoLyte 520 Generic MMP Assay Kit
(AnaSpec) following the manufacturer's instructions. Pro-MMP activa-
tion was achieved after incubating samples with 1mM 4-aminophe-
nylmercuric acetate (APMA) at 37 °C for 4 h (MMP-3) or 40min (MMP-
13). Fluorescence (490 nm excitation λ, 520 nm emission λ) was read
with Wallac Victor II plate reader (Perkin Elmer).
2.7. Statistical analysis
Data are expressed as mean ± standard deviation (SD) of at least 3
independent experiments. Statistical analysis was performed by one-
way or two-way ANOVA using Prism 5 software (GraphPad Software
Inc). Diﬀerences were considered signiﬁcant at p≤ .05.
3. Results
ASC-CM exerted speciﬁc eﬀects on OA-related factors, blunting the
increase of hypertrophic markers induced by TNFα stimulation.
Collagen X expression and Osteocalcin (OC) release were reduced by
18% (day 1) and 37% (day 3) (Fig. 1C and D, Supplementary Fig. 1 A),
while MMP-13 activity was lowered by 61% (Fig. 1F). In addition, ASC-
CM halved the activity of MMP-3, another OA-related cartilage-de-
grading enzyme (Fig. 1E). These were most likely speciﬁc eﬀects. In-
deed, ASC-CM did not induce any alteration in chondrocyte viability
and proliferation (Fig. 1A and B), not even when TNFα signiﬁcantly
increased these parameters (+27% and+31% at day 5 and 7, re-
spectively). Since in the OA context the reduction in MMP-3 and MMP-
13 activity represents a promising goal, we explored its possible causes.
Initially, we investigated MMP expression and release. At an early time
point (24 h after treatments), ASC-CM reduced the expression ofMMP-3
(−49%) and, by a lower extent, MMP-13 (−31%) in TNFα-treated CHs
(Fig. 2A and B). The down-modulation of MMP-3 was maintained up to
day 3 (−38%, data not shown), while MMP-13 one was lost at later
time points (data not shown). Surprisingly, ASC-CM treatment stimu-
lated both the intracellular (Fig. 2C) and the extracellular (Fig. 2E)
levels of MMP-3. The intracellular expression was increased in both
untreated (+81%) and TNFα-treated CHs (+39%) (Fig. 2C and Sup-
plementary Fig. 1 B) and a similar induction was revealed extra-
cellularly (+245% versus control CHs and+ 33% compared to TNFα-
treated cells) (Fig. 2E). On the other hand, ASC-CM caused a mild re-
duction of MMP-13 expression (−12%, Fig. 2D and Supplementary
Fig. 1 B) in TNFα-stimulated CHs, in full accordance with its lower
release (−20%, Fig. 2F). Taken together these evidences cannot explain
the blunting eﬀect of ASC-CM on TNFα-induced MMP activity. Since
MMP activities are physiologically modulated by their endogenous in-
hibitors, we analysed the levels of TIMPs in CH supernatants after
3 days of TNFα stimulation and/or ASC-CM administration. Following
CM treatment, TIMP levels were signiﬁcantly increased in respect to
both control and TNFα-stimulated cells (Fig. 3). TIMP-1 was the more
abundant (> 200 ng/ml), followed by TIMP-2 (around 80 ng/ml),
TIMP-3 (around 5 ng/ml) and the less represented TIMP-4 (Fig. 3A-D
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respectively). Similar levels were already measured after 24 h of
treatments (data not shown). This, together with the analysis of the
naïve treating medium (Table 1), indicates that the high levels of TIMPs
depend on their abundance in ASC secretome rather than to an in-
creased production by treated CHs.
In conclusion, our data suggest that the reduction of MMP activity in
TNFα-stimulated-CHs can be ascribed to the presence of TIMPs in ASC
secretome rather than to its direct modulation of MMP gene and protein
levels. Similar speculations can be made considering other MMPs whose
secretion was enhanced by TNFα, such as MMP-1 (reduced by 31%
following ASC-CM administration), MMP-9 (−52%) and MMP-10
(−16%) (Supplementary Fig. 2).
Moreover, the analysis of the naïve treating medium revealed the
presence of two other factors involved in cartilage protection, namely
OPG and DKK-1 (Table 1). MMP-1, MMP-3 and MMP-10 were also
detected, even though their activity was probably inactivated by TIMPs
Fig. 1. Reduction of hypertrophic markers and MMP activity by ASC-CM treatment in TNFα-stimulated articular chondrocytes. (A) Cell metabolic activity measured
by Alamar Blue assay. Data are shown as mean ± SD (n=3) of relative values calculated as ratios on day 2 (red dashed line). Two-way ANOVA was performed, and
signiﬁcance vs CTRL is shown as *p < .05, **p < .01 and ****p < .0001, vs CM as °°°p < .001. (B) Cell conﬂuency at the ﬁnal time point (day 7) displayed by Diﬀ
Quick staining (100× magniﬁcation; scale bar: 200 μm). (C) Collagen X expression at day 1 by Western Blot. Data (n=4) were normalized on β-Actin and expressed
as relative values (CTRL=1). (D) Osteocalcin (OC) levels in CH culture media (day 3) measured by Luminex Multiplex Assay (n=9 CHs, 3 pools). (E-F) Activity of
MMP-3 and MMP-13 in chondrocyte culture medium (n=10 CHs, 3 pools and 1 single population) expressed as ﬂuorescence units (FU). Data were analysed by one-
way ANOVA followed by Tukey's multiple comparison test. Signiﬁcance vs CTRL is shown as *p < .05, vs CM as °p < .05.
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(e.g. MMP-3 in Fig. 1E).
4. Discussion
The complex nature of osteoarthritis might demand a multifactorial
treatment. Adipose-derived Stromal Cell secretome is a mixture of so-
luble (proteins, lipids and nucleic acids) and vesicular elements, re-
presenting the entire regenerative milieu of its cell source. However, in
the OA context, despite the chondroprotective action of ASCs has been
described in vitro (Manferdini et al., 2013; Maumus et al., 2013; Toﬁno-
Vian et al., 2018), in vivo (Choi et al., 2018; Desando et al., 2013) and
in clinical trials (Lopa et al., 2018), there is no consensus yet on the
eﬃcacy of cell secretome (Manferdini et al., 2015; Platas et al., 2013).
The studies of Platas (Platas et al., 2013), Manferdini (Manferdini et al.,
2015) and Toﬁno-Vian (Toﬁno-Vian et al., 2018) suggest that ASC-CM
action depends on the “activated” status of recipient. Our data conﬁrm
this hypothesis, as in our hands ASC-CM acts on TNFα-stimulated ar-
ticular chondrocytes only. Moreover, the reduction of OA-related fac-
tors did not correlate with a decrease in cell metabolism nor pro-
liferation, providing further evidence of the speciﬁcity of ASC-CM
eﬀects. One of the most promising results is the blunting of the TNFα-
mediated hypertrophic shift. The reduction in MMP-13 activity is par-
ticularly interesting. Indeed, in vivo evidences on MMP-13-deﬁcient or
-depleted mice demonstrate that the action of this hypertrophy-
Fig. 2. Gene, protein expression and extracellular levels of MMP-3 and MMP-13 by ASC-CM-treated and/or TNFα-stimulated chondrocytes. (A-B) MMP-3 (A) and
MMP-13 (B) mRNA expression at day 1 measured by real-time PCR. Data are expressed as 2-ΔΔCt (TBP was used as housekeeping gene). Data were analysed by
Friedman's test followed by Dunn's test. (C-D) MMP-3 (C) and MMP-13 (D) protein expression measured at day 3 by Western Blot. Data (n=7) were normalized on β-
Actin, expressed as relative values (CTRL=1) and analysed using one-way ANOVA followed by Tukey's test. (E-F) MMP-3 (E) and MMP-13 (F) levels measured by
Luminex Multiplex Assay (n= 9 CHs, 3 pools). Signiﬁcance vs CTRL is shown as *p < .05 and ***p < .001, vs CM as °p < .05.
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associated metalloprotease plays a key role in cartilage erosion during
OA onset (Little et al., 2009; Wang et al., 2013). Here, we show that the
ASC-CM-mediated reduction of MMP-13 activity, as well as MMP-3 one,
depends only partially by the modulation of their expression. Indeed,
the downmodulation of MMP-3 and MMP-13 transcription, the latter
fully in agreement with what observed by Toﬁno-Vian (Toﬁno-Vian
et al., 2018), was evident until day 1 only. When we investigated MMP-
13 mRNA levels at subsequent time points (48 and 72 h,-data not
shown-), no clear-cut regulation emerged. A possible explanation is that
the eﬀectors of MMP-13 downmodulation could be active only in a
short time period. As example, several miRNAs are among the major
players involved in MMP-13 inhibition (Li et al., 2017). In this per-
spective, the short-lasting eﬀect of CM could be ascribed to miRNA
limited half-life, usually considered< 24 h. Regardless mRNA, also
intracellular and secreted MMP-13 levels were decreased to a minor
extent compared to the enzymatic activity. Moreover, the inﬂuence of
ASC secretome on MMP-3 protein expression is not consistent with
what observed at mRNA level. Even though this discrepancy was not
expected, a lack of correlation between MMP mRNA and protein levels
has been described before (Lichtinghagen et al., 2002). We hypothesize
that CM reduces both MMP-3 mRNA transcription and its degradation
rate, favouring the translation of MMP-3 and increasing the protein
levels. These aspects might demand further investigations. However, in
our setting, the robust inhibition of MMP-3 and MMP-13 activity is
mainly due to the presence of active TIMPs. Besides MMP-3 and MMP-
13, ASC-CM reduced also the activity of the collagenase MMP-1, the
metallopeptidase MMP-12 and MMP-9/10, both Aggrecan-degrading
enzymes (preliminary data not shown). The presence of these inhibitors
in the secretome of MSCs is particularly interesting considering the
relevance of developing clinical grade MMP inhibitors (Liu and Khalil,
2017). Of note, TIMPs in ASC secretome did not alter the physiologic
MMP activity but buﬀered the TNFα-induced one. In the OA context, it
is noteworthy that TIMPs are known to inhibit other metalloprotei-
nases, namely ADAM-10 (a disintegrin and metalloproteinase-10),
ADAM-12, ADAMTS-4 (a disintegrin and metalloproteinase with
thrombospondin motif) and ADAMTS-5 (Liu and Khalil, 2017; Yang
et al., 2017). Moreover, TIMP-1 has been implicated in the reduction of
angiogenesis mediated by MSC secretome (Zanotti et al., 2016). Con-
sequently, ASC-CM could also play a role in re-establishing the anti-
angiogenic environment of a healthy cartilage.
Fig. 3. TIMP levels in ASC-CM-treated and/or TNFα-stimulated chondrocyte culture media. (A-D) TIMP-1 (A), TIMP-2 (B), TIMP-3 (C) and TIMP-4 (D) levels
measured by Luminex Multiplex Assay (n=10 CHs, 3 pools and 1 single population). Data were analysed by one-way ANOVA followed by Tukey's multiple
comparison test. Signiﬁcance vs CTRL is shown as *p < .05, **p < .01 and *** < 0.001, vs CM as °p < .05 and vs TNFα as § p < .05, §§ p < .01 and §§§
p < .001.
Table 1
Concentrations of factors in the treating medium containing ASC-CM. Protein
levels were measured by Luminex Multiplex Assay.
[] of factors in the treating medium containing ASC-CM (pg/ml)
TIMP-1 2.6×105
TIMP-2 2.7×104
TIMP-3 3.8×103
TIMP-4 166
OC nd
OPG 1.1–1.9× 103
DKK-1 1.8–2.1× 103
MMP-1 2.1–2.6× 103
MMP-3 1.9–2.1× 103
MMP-9 nd
MMP-10 17.7–20.3
MMP-12 0–56
MMP-13 nd
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Besides TIMPs, other cartilage-protecting factors, namely OPG and
DKK-1, were detected in ASC-CM (Table 1). OPG is known to prevent
cartilage degradation by inhibiting proteoglycan loss and chondrocyte
apoptosis (Feng et al., 2015; Kadri et al., 2008) while DKK-1 acts mainly
by preserving CH phenotype, counteracting hypertrophy (Zhong et al.,
2016) and inhibiting the expression of catabolic factors (Oh et al.,
2012). Of note, we have recently shown that DKK-1 is one of the 34
proteins more abundantly secreted by ASCs compared with dermal ﬁ-
broblast (Niada et al., 2018).
In the last few years, the ﬁrst in vivo evidences of the beneﬁcial
eﬀect of MSC-secretome administration in pre-clinical OA models have
been produced (Cosenza et al., 2017; Khatab et al., 2018; Tao et al.,
2017; Toh et al., 2017; Wang et al., 2017; Zhang et al., 2018; Zhu et al.,
2017). Even though many of these experimental plans rely on the ad-
ministration of the puriﬁed vesicular component, Khatab et al. showed
the eﬀects of the whole secretome (Khatab et al., 2018) on pain re-
duction and arrest of cartilage damage in a murine collagenase OA
model. The rationale of their choice relies on the lack of current
knowledge on which component plays a major role. We chose to use a
cell product containing both freely dissolved factors and vesicular
components (Supplementary Fig. 3) for the same reason. Moreover, in
the OA context, the use of selected CM subcomponents may lead to a
diminished eﬃcacy of the treatment. In fact, many factors released by
ASCs that can be therapeutically exploited are both conveyed in vesicles
and released as soluble mediators. TIMPs have been described both in
the whole secretome (Niada et al., 2018)(Egashira et al., 2012; Kono
et al., 2014; Maﬃoli et al., 2017) and in the vesicular elements (exo-
somes or microvesicles) (Haraszti et al., 2016). Similarly, DKK-1, HGF,
recognized as a mediator of ASC anti-ﬁbrotic eﬀect (Maumus et al.,
2013), and Prostaglandin E2, an immunosuppressive factor acting also
on chondrocyte hypertrophic shift (Li et al., 2004; Manferdini et al.,
2013), have been identiﬁed both in whole ASC-CM (Manferdini et al.,
2013; Maumus et al., 2013) and in vesicles (vesiclepedia (Pathan et al.,
2019)). Therefore, the use of secretome fractions would subtract ef-
fectors at the additional cost of increasing manipulations. This is par-
ticularly risky, also considering how diﬀerent isolation methods can
alter EV content (Gualerzi et al., 2019).
In conclusion, ASC-CM might constitute a novel tool to counteract
OA development. It inhibits the aberrant activity of MMPs and blunts
the hypertrophic changes induced by the inﬂammatory cytokine TNFα
(Graphical Abstract). This complete cell product can be easily obtained,
prepared in advance and stored. Therefore it constitutes a ready-to-use
product. Both the soluble factors and the extracellular vesicles released
by ASCs may be responsible of CM beneﬁcial action, including its well-
known anti-inﬂammatory properties. Further investigations should aim
at disclosing all the components of the secretome that are involved in its
therapeutic role in the perspective of a future clinical setting.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2019.101463.
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